Brivaracetam for the treatment of epilepsy

Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)

(2015) Meir Bialer et al.   EPILEPSY RESEARCH

Brivaracetam Single and Multiple Rising Oral Dose Study in Healthy Japanese Participants: Influence of CYP2C19 Genotype

(2014) Armel Stockis et al.   Drug Metabolism and Pharmacokinetics

Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: A randomized, double-blind, placebo-controlled study

(2014) Armel Stockis et al.   EPILEPSIA

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial

(2013) Victor Biton et al.   EPILEPSIA

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial

(2013) Patrick Kwan et al.   EPILEPSIA

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial

(2013) Philippe Ryvlin et al.   EPILEPSIA

Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women

(2013) Armel Stockis et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Brivaracetam Disposition in Mild to Severe Hepatic Impairment

(2013) Armel Stockis et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

Brivaracetam Disposition in Renal Impairment

(2012) Maria Laura Sargentini-Maier et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Patterns of treatment response in newly diagnosed epilepsy

(2012) M. J. Brodie et al.   NEUROLOGY

Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma

(2011) Wolfgang Löscher et al.   EPILEPSIA

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Estimation of the burden of active and life-time epilepsy: A meta-analytic approach

(2010) Anthony K. Ngugi et al.   EPILEPSIA

Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)

(2010) Meir Bialer et al.   EPILEPSY RESEARCH

Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats

(2010) E.R. Detrait et al.   EPILEPSY RESEARCH

Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial

(2010) J. A. French et al.   NEUROLOGY

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

(2008) Paul Rolan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Brivaracetam: a rational drug discovery success story

(2008) M A Rogawski   BRITISH JOURNAL OF PHARMACOLOGY

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of brivaracetam on cardiac repolarisation – a thorough QT study

(2008) D. Rosillon et al.   CURRENT MEDICAL RESEARCH AND OPINION

SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

(2007) Rafal M. Kaminski et al.   NEUROPHARMACOLOGY